High Quality Biapenem CAS 120410-24-4 In Stock

Biapenem CAS: 120410-24-4 is a 1-beta-methylcarbapenem antibiotic with a wide range of antibacterial activity. Biapenem has similar antibacterial activity to that of imipenem, but is more stable against human renal dehydropeptidase-I and with less neurotoxicity. Biapenem CAS: 120410-24-4 is a carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively. It has a role as an antibacterial drug. It is a member of carbapenems, a pyrazolotriazole and an organic sulfide. Biapenem CAS: 120410-24-4 is stable to most β-lactamases, including AmpC and extended-spectrum β-lactamases (ESBLs), with a broad spectrum activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria1,2. It combines with penicillin binding proteins and inhibits bacterial cell wall synthesis. Owing to the 1-β-methyl group, biapenem is more stable against the hydrolysis by human renal dehydropeptidase-I (DHP-I) than is meropenem3. Thus, in contrast to imipenem and panipenem, which must be compounded with a renal dehydropeptidase inhibitor, biapenem could be administrated independently. Meanwhile, its structure of triazole cations enhances its outer membrane permeability to Gram-negative bacteria. It is distributed widely in tissues, especially in the urinary tract, lungs and liver. However, no randomized controlled clinical trials have been published to compare the clinical efficacy, bacterial eradication rates and safety between biapenem and meropenem in the treatment of bacterial infections. We, therefore, conducted a multicenter, randomized, parallel-controlled clinical trial in nine tertiary care teaching hospitals in China to compare biapenem and meropenem in the treatment of bacterial lower respiratory tract infections and urinary tract infections (UTIs).
Chat Now

Product Details

--2_01.png

Product Description

Name

High quality Biapenem 120410-24-4 in stock

Other name

(4R,5S,6S)-3-(6,7-Dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-ylsulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

CAS

120410-24-4 

Appearance

White powder

Biapenem CAS: 120410-24-4 is a 1-beta-methylcarbapenem antibiotic with a wide range of antibacterial activity. Biapenem has similar antibacterial activity to that of imipenem, but is more stable against human renal dehydropeptidase-I and with less neurotoxicity.

Biapenem CAS: 120410-24-4 is a carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively. It has a role as an antibacterial drug. It is a member of carbapenems, a pyrazolotriazole and an organic sulfide.

Biapenem  CAS: 120410-24-4 is stable to most β-lactamases, including AmpC and extended-spectrum β-lactamases (ESBLs), with a broad spectrum activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria1,2. It combines with penicillin binding proteins and inhibits bacterial cell wall synthesis. Owing to the 1-β-methyl group, biapenem is more stable against the hydrolysis by human renal dehydropeptidase-I (DHP-I) than is meropenem3. Thus, in contrast to imipenem and panipenem, which must be compounded with a renal dehydropeptidase inhibitor, biapenem could be administrated independently. Meanwhile, its structure of triazole cations enhances its outer membrane permeability to Gram-negative bacteria. It is distributed widely in tissues, especially in the urinary tract, lungs and liver. However, no randomized controlled clinical trials have been published to compare the clinical efficacy, bacterial eradication rates and safety between biapenem and meropenem in the treatment of bacterial infections. We, therefore, conducted a multicenter, randomized, parallel-controlled clinical trial in nine tertiary care teaching hospitals in China to compare biapenem and meropenem in the treatment of bacterial lower respiratory tract infections and urinary tract infections (UTIs).

120410-24-4 .jpg


Inquiry